Insider · CIK 0001907094
James P Moran
Files at IGC (IGC Pharma, Inc.). First filing -, latest -.
James P Moran files SEC Form 4 as director at IGC (IGC Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James P Moran has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | IGC IGC Pharma, Inc. | MOption exercise Common Stock | +80,000 | $0.00 | $0 | 1,185,735 | Apr 6, 2026 |
| Apr 1, 2026 | IGC IGC Pharma, Inc. | MOption exercise Common Stock | +50,000 | $0.00 | $0 | 1,235,735 | Apr 6, 2026 |
| Apr 1, 2026 | IGC IGC Pharma, Inc. | MOption exercise Restricted Stock Unitsderivative | -80,000 | $0.00 | $0 | 0 | Apr 6, 2026 |
| Apr 1, 2026 | IGC IGC Pharma, Inc. | MOption exercise Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 50,000 | Apr 6, 2026 |
| Oct 17, 2025 | IGC IGC Pharma, Inc. | AGrant or award Optionsderivative | +500,000 | $0.00 | $0 | 500,000 | Oct 21, 2025 |
Questions about James P Moran
Answered from the filings on this page, as of the latest one.
Is James P Moran buying or selling?
James P Moran has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James P Moran's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James P Moran has 0.
Where does James P Moran file Form 4?
James P Moran has filed Form 4 at IGC (IGC Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.